Making Your Own Luck
This article was originally published in Start Up
Executive Summary
Amgen's now shuttered Boulder R&D operation--which it had created from its 1994 acquisition of Synergen--was supposed to be joint ventured. No other companies wanted in and now the former head of the Boulder group is trying to create a new discovery services company, Source Biopharmaceuticals, from some Amgen R&D projects and a core of former Amgen-Boulder scientists. But Amgen hasn't made up its mind on whether it wants to let the projects go--and it will be tough to get VCs or corporate partners to sign up without the licenses. Meanwhile, another group of former Amgen scientists, this time chemists, have decided to create their own discovery services company, entirely without Amgen technology, raising $7mm to do so.
You may also be interested in...
Commercializing Rare Disease Therapies Is Getting Tougher
For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.
Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?
A Learning Lab For Outcomes-Based Risk-Sharing Agreements
Merck and UnitedHealth's Optum group have partnered to explore various value constructs.